Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH

Medical Oncology

Contact Information

Office Phone Number





617-632-2175 (new patients)
617-632-3800 (established patients)


Sara M. Tolaney, MD, MPH

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. 



Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers
Associate Director, Susan F. Smith Center for Women's Cancers
Senior Physician
Associate Professor of Medicine, Harvard Medical School


Clinical Interests

Breast oncology, Immuno-oncology, Novel therapeutics

Diseases Treated

Board Certification

  • Hematology
  • Internal Medicine
  • Medical Oncology


  • Dana-Farber/Partners CancerCare, Hematology & Oncology


  • Johns Hopkins Hospital, Internal Medicine

Medical School

  • University of California, San Francisco School of Medicine


    Sara Tolaney, MD, MPH is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute.  Dr. Tolaney has earned both a strong national and international reputation as a talented clinical investigator and is key opinion leader in breast oncology. She has done extensive work on de-escalating therapy for patients with low-risk HER2-positive breast cancer, having developed a less toxic treatment regimen associated with a clinically low event rate.  This regimen is incorporated into national and international treatment guidelines, and she has follow-up multi-institutional studies ongoing to evaluate if even less toxic therapies may have a role in these patients.  She's also been instrumental in the development of cdk 4/6 inhibitors in breast cancer and served as the international co-PI for the first randomized study of cdk 4/6 inhibitors in HER2-positive breast cancer and having served on the steering committee for the study leading to the first approval of cdk 4/6 inhibitors in the adjuvant setting.  Dr. Tolaney has also been instrumental in developing antibody drug conjugates, having helped lead several registration trials with these novel therapies. Moreover, she has played a pivotal role in developing a series of investigator initiated clinical trials in immunotherapy, with strong translational endpoints.  Dr. Tolaney currently serves as the Chief of the Division of Breast Oncology, overseeing the department and mentors several junior faculty and fellows in their careers.  Importantly, Dr. Tolaney is also an outstanding clinician, recognized by her peers for her excellent patient care with the "Lee Nadler Extra Mile Award" and is a Senior Physician at DFCI.




    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Sara M. Tolaney, MD, MPH

    About Our Ratings

    Physician Star Rating Comment Block